David Gauden is the Chief Executive Officer (CEO) of Blue Earth Therapeutics Ltd. A co-founder of sister company, Blue Earth Diagnostics, established in 2014, he was instrumental in rapidly advancing its portfolio and building the company from a start-up into a successful global organization. Previously David was Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the portfolio mix, licensing, product development and strategic marketing activities for a range of developmental PET drugs. Now with more than 20 years in the medical imaging industry, David has deep expertise across the business spectrum. David has an undergraduate degree from the University of Warwick and a doctorate in Biochemistry from the University of Oxford.
Blue Earth Therapeutics Board
BLUE EARTH THERAPEUTICS' BOARD MEMBERS
Our Directors come from a wide-range of relevant backgrounds and make an active contribution to company strategy.
Fulvio Renoldi Bracco holds a degree in Economics from “Bocconi” University in Milan where he graduated with a final dissertation based on US and EU regulations on Mergers and Acquisitions.
He subsequently spent four years in Citibank in London, New York and Milan where he finally specialized in structured finance products for the financial institution industry.
Since 1996, he joined his family in the management of Bracco S.p.A., where he initially worked in the corporate Finance Department.
In 2002 he became Chairman and CEO of Acist, a US Affiliate of the Bracco Group, specialized in the development manufacturing and marketing of proprietary cutting edge medical systems.
In April 2009 he became the head of the Global Business Unit Imaging of Bracco Imaging S.p.A., one of the World’s leading companies in the diagnostic imaging business. Part of Bracco S.p.A., the holding company of Bracco Group, Bracco Imaging operates in over 90 markets worldwide, either directly or indirectly through subsidiaries, joint ventures, license and distribution partnership agreements.
In June 2017 he was appointed Chief Executive Officer of Bracco Imaging S.p.A.
He is a member of the Presidential Committee of Federchimica, – the Italian Federation of the chemical industry – of the BoD of the American Chamber of Commerce in Italy and of the BoD of Endeavor Italy.
In addition he is member of the BoD of Bracco S.p.A. and Centro Diagnostico Italiano.
He is married with two sons
Andrea, who joined Equita – the leading independent investment bank in Italy – in 2008 as Head of Investment Banking, today is Chief Executive Officer at Equita, member of the ASSOSIM executive committee, the Italian Association of Financial Markets Intermediaries, member of the stakeholder group of CONSOB, Italy’s financial markets supervisor, and of the Advisory Board to Borsa Italiana, the Italian Stock Exchange. Andrea is also a member of the Board of Directors of Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK.
Andrea has developed relevant expertise in capital markets and investment banking during his thirty-years experience. He began his career in London in 1990, at Goldman Sachs International, where he spent five years in the Corporate Finance and Debt Capital Markets departments. Between July 1995 and January 2006, Andrea divided his time between the Milan and London offices of Barclays, de Zoete Wedd (later acquired by Credit Suisse) and Credit Suisse, first as a member of the M&A team, then as Head of Equity Capital Markets for the Italian and Southern European markets in London and later as a senior coverage officer and legal representative of CSFB’s Italian branch in Milan. Andrea also worked as a freelance consultant for large industrial groups between April 2006 and December 2007.
He graduated Magna cum laude in Business Administration from the Bocconi University in Milan, with part of his studies at the New York University.
Andrea Scampoli is a Director at Blue Earth Therapeutics and is the Chief Financial Officer at Blue Earth Diagnostics. Andrea has many years’ experience in Pharmaceuticals and Diagnostics and joined the Bracco Group in 2013. Andrea has held several senior finance roles in different businesses and companies including Bracco Imaging Sp.A, DHL Express, PepsiCo and GE Industrial. Andrea has a Bachelor's degree in Business Administration.
Cyrille joined Bracco S.p.A. in 2019 as Chief Corporate Development Officer and Head of Strategic Initiatives.
Cyrille started his career in investment banking, at Goldman Sachs in London then joined General Electric, where he had a 15-year tenure holding various position in Global Business Development. He left to join the executive committee of Smith & Nephew plc, as Chief Corporate Development Officer and Head of Global Business Services.
Cyrille has a strong track-record in strategy, M&A, building global support functions, running integration, cost reduction programs, and advising boards. He sits on the board of several medical technology companies, including Virbac, Polarean and Reapplix.
Cyrille holds a Master’s degree in Finance from HEC Paris.
Fabio started his career at Bruker as an Application Specialist and Project Leader, moving to Bracco Imaging S.p.A. in 2008. Starting as Preclinical Imaging Department Manager in the R&D Centre based in Ivrea, he subsequently held the position of Director of the same Centre and today the role of Director of R&D of the Global Business Unit Imaging of Bracco.
Fabio is also Managing Director of SurgVision GmBH, member of the Board of Directors of Blue Earth Diagnostics as well as of the Gruppo Tecnico Ricerca e Sviluppo of Confindustria and of the Gruppo Tecnico Università e Ricerca of Assolombarda.
His scientific CV includes approximately 45 peer-reviewed manuscripts and 10 patents.
Fabio holds a Ph.D. in Physics from the University of Pavia.
Chelsea is an intellectual property (IP) lawyer with commercial, corporate, litigation and governance experience. Dual-qualified as an English Solicitor and Australian Legal Practitioner, Chelsea started her career as a Nuclear Medicine Technologist, having obtained an undergraduate degree in Medical Radiation before studying law. She worked for several years at international law firms Bird & Bird LLP and Herbert Smith Freehills in London, Melbourne and The Hague advising clients in the life sciences sector. Most recently, Chelsea was Associate Director at LifeArc supporting translational research and funding activity. Chelsea completed postgraduate IP studies at the University of Oxford in 2012 and is a member of the BioIndustry Association IP Advisory Committee. She is also an Independent Trustee at the Institute of Physics and Engineering in Medicine.